Literature DB >> 11858877

Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.

Bert E Johansson1, Barbara A Pokorny, Vincent A Tiso.   

Abstract

Influenza viruses neuraminidase (NA) were chromatographically extracted from influenza viruses A/Nanchang/933/95 H3(NC)N2(NC) [R] and A/Johannesburg/82/96 H1(JH)N1(JH) [R] and used to supplement conventional inactivated trivalent influenza vaccine. Immunization of mice with this preparation resulted in high titers of antibodies to both hemagglutinins (HA) and neuraminidases (NA); there were no significant differences in the anti-HA antibody titers between the conventional and the supplemented vaccine preparation. Likewise, there were no significant differences in anti-NA antibody titers between the supplemented vaccine and titers from mice immunized with a neuraminidase vaccine containing a mixture of N1-NA and N2-NA. There was no evidence of a diminution of the immune response to the HA components of the vaccine despite the presence of antigenically equivalent amounts of both N1-NA and N2-NAs. Homotypic and distantly related heterotypic infections for both H1, N1 and H3N2 subtypes were suppressed and greater reduction in pulmonary virus titers (PVT) were observed in the trivalent vaccine supplemented with purified neuraminidase from each subtype, N1 and N2. Effects on the influenza B viral components were not studied. Previous studies on supplementation of conventional influenza vaccine focused only on monovalent H3N2 vaccine preparations; this study demonstrates in a mouse model system that supplementation of trivalent influenza vaccine with both influenza A subtype neuraminidases, N1 and N2 is highly immunogenic for HA and NA of each subtype and efficacious in protecting against influenza from homotypic and heterotypic infectious challenges of either subtype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858877     DOI: 10.1016/s0264-410x(01)00490-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays.

Authors:  Caroline Gravel; Changgui Li; Junzhi Wang; Anwar M Hashem; Bozena Jaentschke; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  J Vis Exp       Date:  2011-04-04       Impact factor: 1.355

2.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

3.  Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Authors:  Berend Jan Bosch; Rogier Bodewes; Robert P de Vries; Joost H C M Kreijtz; Willem Bartelink; Geert van Amerongen; Guus F Rimmelzwaan; Cornelis A M de Haan; Albert D M E Osterhaus; Peter J M Rottier
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

Review 4.  Developments of subunit and VLP vaccines against influenza A virus.

Authors:  Ma-ping Deng; Zhi-hong Hu; Hua-lin Wang; Fei Deng
Journal:  Virol Sin       Date:  2012-06-09       Impact factor: 4.327

5.  Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.

Authors:  Alaina J Mooney; Jon D Gabbard; Zhuo Li; Daniel A Dlugolenski; Scott K Johnson; Ralph A Tripp; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

6.  Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.

Authors:  Ki-Hye Kim; Young-Tae Lee; Soojin Park; Yu-Jin Jung; Youri Lee; Eun-Ju Ko; Yu-Jin Kim; Xuguang Li; Sang-Moo Kang
Journal:  Virology       Date:  2019-07-08       Impact factor: 3.616

7.  Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy.

Authors:  Jin Gao; Laura Klenow; Lisa Parsons; Tahir Malik; Je-Nie Phue; Zhizeng Gao; Stephen G Withers; John Cipollo; Robert Daniels; Hongquan Wan
Journal:  J Virol       Date:  2021-10-06       Impact factor: 5.103

8.  Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Authors:  Zach Menne; Vasilis C Pliasas; Richard W Compans; Sheniqua Glover; Constantinos S Kyriakis; Ioanna Skountzou
Journal:  Virology       Date:  2021-08-05       Impact factor: 3.513

9.  Development of neuraminidase subtype-specific reference antisera by recombinant protein expressed in baculovirus.

Authors:  Kyu-Jun Lee; Jun-Gu Choi; Hyun-Mi Kang; Kwang-Il Kim; Choi-Kyu Park; Youn-Jeong Lee
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

10.  The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets.

Authors:  Zhongying Chen; Lomi Kim; Kanta Subbarao; Hong Jin
Journal:  Vaccine       Date:  2012-02-11       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.